Skip to main content
NeuronFeed
Home Investors ARCH Venture Partners

ARCH Venture Partners

Active VC
Portfolio Active
3
Latest Treeline Biosciences
Deal flow
$659M
5 rounds
Unicorns
0
≥ $1B valuation
Founded
—
Latest
Dec 2025
Paradigm Health

About ARCH Venture Partners

Venture capital firm tracking 3 AI investments, with focus on Drug Discovery and US startups. Total tracked deal flow: $659M.

Sector focus

💊 Drug Discovery 5
🏥 AI Healthcare 3
🩺 AI Medical 1

Geographic focus

US 2

Portfolio

3

Treeline Biosciences

Computational and experimental drug discovery for hard-to-drug cancer targets

Paradigm Health

AI research platform making clinical trials part of routine patient care

Ollin Biosciences

Co-investors

8

Mubadala Capital

3 shared

F-Prime

3 shared

Lux Capital

3 shared

General Catalyst

3 shared

GV (Google Ventures)

3 shared

DFJ Growth

2 shared

American Cancer Society BrightEdge Fund

1 shared

Monograph Capital

1 shared

Recent rounds

5
Dec 4, 2025 Series B $78M Lead Paradigm Health
Aug 21, 2025 Series A $200M Treeline Biosciences
Series A $203M Paradigm Health
Series B $78M Paradigm Health
Series A $100M Ollin Biosciences